尿液与血清S100A8/A9及S100A12与活动性狼疮肾炎相关并可能预测利妥昔单抗治疗反应
本研究基于BILAG-BR研究,检测243例SLE患者及48名年龄匹配对照的血清和尿液S100A8/A9与S100A12水平,评估其作为活动性狼疮肾炎生物标志物及预测利妥昔单抗(RTX)治疗反应的能力。结果显示尿液及尿/血清比值在活动性LN中升高,且在抗dsDNA抗体阳性患者中表现更佳;血清S100A8/A9与S100A12联合可预测6个月后RTX治疗反应。
要点
- 尿液S100及尿/血清比值在活动性狼疮肾炎患者中升高。
- S100蛋白在抗dsDNA抗体阳性SLE患者中作为活动性LN标志物表现更佳。
- 血清S100A8/A9与S100A12联合可预测LN患者6个月RTX治疗反应。
核心结论
- S100蛋白有望用于预测SLE活动性肾脏病变及利妥昔单抗治疗反应。
研究设计与样本
- 研究纳入BILAG-BR研究中243例SLE患者及48名年龄匹配对照,采用Meso Scale Discovery技术定量血清和尿液S100A8/A9与S100A12。
主要发现
- 血清S100A12(p<0.001)及血清和尿液S100A8/A9(p<0.001)在SLE患者中升高。
- 血清和尿液S100水平与全球疾病活动度(SLE疾病活动指数)不相关。
- 尿液S100水平及尿/血清比值在活动性LN患者中升高。
- S100蛋白在抗双链DNA抗体阳性SLE患者中作为活动性LN生物标志物表现更好。
- 二元逻辑回归和曲线下面积分析提示血清S100A8/A9与S100A12联合可预测LN患者6个月后RTX治疗反应。
临床怎么用
- 可考虑检测尿液S100及尿/血清比值辅助识别活动性狼疮肾炎,尤其在抗dsDNA抗体阳性患者中。
- 血清S100A8/A9与S100A12联合或有助于预测LN患者对利妥昔单抗的治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Approaches and the Engineering Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of calcium-binding S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab (RTX) in LN. METHODS: S100A8/A9 and S100A12 proteins were quantified in the serum and urine of 243 patients with SLE from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) study and 48 controls matched for age using Meso Scale Discovery's technology to determine whether they perform as biomarkers for active LN and/or may be used to predict response to treatment with RTX. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment. RESULTS: Serum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) levels are elevated in patients with SLE. While serum and urine S100 levels do not correlate with global disease activity (SLE Disease Activity Index), levels in urine and urine/serum ratios are elevated in patients with active LN. S100 proteins perform better as biomarkers for active LN involvement in patients with SLE who tested positive for anti-double-stranded DNA antibodies. Binary logistic regression and area under the curve analyses suggest the combination of serum S100A8/A9 and S100A12 can predict response to RTX treatment in LN after 6 months. CONCLUSIONS: Findings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with RTX.
引用
- Davies JC, Midgley A, Carlsson E, et al. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 2020. PMID: 32723832. doi:10.1136/rmdopen-2020-001257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。